Fig. 1

Better tumor control and overall survival of tumor-bearing mice after combination treatment with hRT and IL-2c. a Scheme of IL-2c. b Treatment scheme. In the combination treatment groups, the daily i.p. injections of equimolar doses of IL-2 or IL-2c started 4 days after hRT. Tumor growth (c) and survival (d) of CD133-B16 melanoma-bearing mice which were either untreated or treated with IL-2c, 2 × 12 Gy, 2 × 12 Gy + IL-2, or 2 × 12 Gy + IL-2c. The effects of the depletion of either CD8+ T cells or NK cells are also shown. e Long-term survival of mice after combined treatment with hRT and IL-2c is associated with the development of vitiligo. f Mice cured from established B16 tumors are immune to re-challenge with CD133-B16 cells but not LLC cells. g, h Tumor growth (g) and survival (h) of mice bearing C51 colon carcinomas which were either untreated or treated with IL-2c, 2 × 8 Gy, 2 × 8 Gy + IL-2, or 2 × 8 Gy + IL-2c. i, j Tumor growth (i) and survival (j) of mice bearing 4T1 mammary carcinomas which were either untreated or treated with IL-2c, 2 × 12 Gy, 2 × 12 Gy + IL-2, or 2 × 12 Gy + IL-2c